Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease
- 4 January 2022
- journal article
- research article
- Published by Springer Nature in Neurological Sciences
- Vol. 43 (5) , 3187-3193
Abstract
Background Subthalamic nucleus deep brain stimulation (STN-DBS) is an effective surgical treatment for advanced Parkinson’s disease (PD). However, some patients still experience motor fluctuations or dyskinesia after STN-DBS. Safinamide is approved as add-on treatment to levodopa in fluctuating PD patients. In this study, we evaluated the effect of safinamide as adjunctive therapy in PD patients still experiencing motor fluctuations and dyskinesias after STN-DBS. Methods PD patients treated for at least 2 years with bilateral STN-DBST and with troublesome motor fluctuation and/or dyskinesias were examined by means of the Movement Disorders Society—Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), the quality of life questionnaire Parkinson’s Disease Questionnaire-8 (PDQ-8) and the Non-Motor Symptoms Scale (NMSS) at baseline (T0), after 1 month of treatment with safinamide 50 mg daily (T1) and after another month of treatment with safinamide 100 mg daily (T2). Results Twenty-nine PD patients were examined. An improvement of the MDS-UPDRS IV score (motor complications) was observed between T0 and T1, T0 and T2, and T1 and T2. The time spent in the OFF state, the functional impact and the complexity of motor fluctuations significantly improved between T0 and T1 and T0 and T2. The mean levodopa equivalent daily dose significantly decreased from T0 to T1 and from T0 to T2. Regarding non-motor symptoms, an improvement on mood and pain was observed. Conclusions Safinamide seems to be an effective adjunctive treatment in PD patients treated with bilateral STN-DBS, leading to an improvement of motor complications, mood and pain.Keywords
This publication has 34 references indexed in Scilit:
- Non-dopaminergic Treatments for Motor Control in Parkinson’s DiseaseDrugs, 2013
- Beyond nine years of continuous subthalamic nucleus deep brain stimulation in Parkinson's diseaseMovement Disorders, 2011
- Systematic review of levodopa dose equivalency reporting in Parkinson's diseaseMovement Disorders, 2010
- Glutamatergic Modulators: The Future of Treating Mood Disorders?Harvard Review of Psychiatry, 2010
- The Role of the Tripartite Glutamatergic Synapse in the Pathophysiology and Therapeutics of Mood DisordersThe Neuroscientist, 2009
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing resultsMovement Disorders, 2008
- The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot studyMovement Disorders, 2007
- Glutamate receptors and painSeminars in Cell & Developmental Biology, 2006
- The effect of deep brain stimulation on quality of life in movement disordersJournal of Neurology, Neurosurgery & Psychiatry, 2005
- The PDQ-8: Development and validation of a short-form parkinson's disease questionnairePsychology & Health, 1997